sulcardine (HBI-3000) / HUYA Bioscience 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   16 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sulcardine (HBI-3000) / HUYA Bioscience
2022-001021-74: A Study to Assess how Safe and Effective HBI-3000 is for the Conversion of Atrial Fibrillation (AF) of Recent Onset

Not yet recruiting
2
150
Europe
HBI-3000 (Sulcardine Sulfate), HBI-3000, Powder for solution for infusion
HUYABIO International, LLC, HUYABIO International, LLC
Sustained atrial fibrillation (AF) of over 2 hours and <72 hours duration up to the time of dosing, eligible for cardioversion (electrical and pharmacologic), Sustained atrial fibrillation (AF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04680026: A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Active, not recruiting
2
150
Canada, US, RoW
HBI-3000, sulcardine sulfate, Placebo
HUYABIO International, LLC.
Atrial Fibrillation
12/24
12/24

Download Options